The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET)

Stroke. 2010 Feb;41(2):295-9. doi: 10.1161/STROKEAHA.109.562827. Epub 2010 Jan 7.

Abstract

Background and purpose: In ischemic stroke, the site of arterial obstruction has been shown to influence recanalization and clinical outcomes. However, this has not been studied in randomized controlled trials, nor has the impact of arterial obstruction site on reperfusion and infarct growth been assessed. We studied the influence of site and degree of arterial obstruction patients enrolled in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET).

Methods: EPITHET was a prospective, randomized, placebo-controlled trial of intravenous tissue plasminogen activator (tPA) in the 3- to 6-hour time window. Arterial obstruction site and degree were rated on magnetic resonance angiography blinded to treatment allocation and outcomes.

Results: In 101 EPITHET patients, 87 had adequate quality magnetic resonance angiography, of whom 54 had baseline arterial obstruction. Infarct growth attenuation was greater in those with tPA treatment compared to placebo among patients with middle cerebral artery (MCA) obstruction (P=0.037). The treatment benefit of tPA over placebo in attenuating infarct growth was greater for MCA than internal carotid artery (ICA) obstruction (P=0.060). With tPA treatment, good clinical outcome was more likely with MCA than with ICA obstruction (P=0.005). Most patients with ICA obstruction did not achieve good clinical outcome, whether treated with tPA (100%) or placebo (77%). The study was underpowered to prove any treatment benefit of tPA among patients with any or severe degree of arterial obstruction.

Conclusions: Arterial obstruction site strongly predicts outcomes. ICA obstruction carries a uniformly poor prognosis, whereas good outcomes with MCA obstruction are associated with tPA therapy.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antifibrinolytic Agents / administration & dosage
  • Antifibrinolytic Agents / adverse effects
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology*
  • Brain Ischemia / physiopathology
  • Carotid Artery Thrombosis / drug therapy
  • Carotid Artery Thrombosis / pathology
  • Carotid Artery Thrombosis / physiopathology
  • Cerebral Arteries / drug effects
  • Cerebral Arteries / pathology
  • Cerebral Arteries / physiopathology
  • Emergency Medical Services / methods
  • Emergency Medical Services / statistics & numerical data
  • Female
  • Humans
  • Image Processing, Computer-Assisted / methods
  • Infarction, Middle Cerebral Artery / drug therapy
  • Infarction, Middle Cerebral Artery / pathology
  • Infarction, Middle Cerebral Artery / physiopathology
  • Injections, Intravenous / statistics & numerical data
  • Intracranial Thrombosis / drug therapy*
  • Intracranial Thrombosis / pathology*
  • Intracranial Thrombosis / physiopathology
  • Magnetic Resonance Angiography / methods*
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care
  • Predictive Value of Tests
  • Prospective Studies
  • Severity of Illness Index
  • Thrombolytic Therapy / methods
  • Thrombolytic Therapy / statistics & numerical data*
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / adverse effects
  • Treatment Outcome

Substances

  • Antifibrinolytic Agents
  • Tissue Plasminogen Activator